The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 20, 2025
Filed:
Nov. 07, 2019
Applicant:
Crispr Therapeutics Ag, Zug, CH;
Inventors:
Jonathan Alexander Terrett, Cambridge, MA (US);
Jason Sagert, Cambridge, MA (US);
Assignee:
CRISPR THERAPEUTICS AG, Zug, CH;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3015 (2013.01); A61K 39/3955 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/4202 (2025.01); A61K 40/421 (2025.01); A61P 35/00 (2018.01); C07K 14/4717 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 19/00 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2239/49 (2023.05); A61K 2239/56 (2023.05); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2310/20 (2017.05); C12N 2502/30 (2013.01); C12N 2502/99 (2013.01); C12N 2510/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01);
Abstract
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1malignancies.